UK markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
60.540.00 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close60.54
Bid56.79 x 900
Ask62.00 x 900
Day's range60.44 - 61.24
52-week range56.79 - 195.74
Avg. volume314,019
Market cap3.99B
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-4.48
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est93.80
  • Here's Why Galapagos Stock Is Falling Today
    Motley Fool

    Here's Why Galapagos Stock Is Falling Today

    Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday. Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors.

  • Galapagos (GLPG) Falls on Inflammatory Study Data Readout

    Galapagos (GLPG) Falls on Inflammatory Study Data Readout

    Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

  • Globe Newswire

    Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Generally safe and well toleratedPositive efficacy signal in psoriasis patients at Week 440% of patients showed improvement of at least 50% in PASI response (PASI 50) with high dose of GLPG3667 at Week 4Data support initiation of Phase 2b dose finding study in psoriasis Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patient